Novartis AG
Novartis Campus
4002 Basel
Switzerland
Telephone : +41 61 324 1111
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
January 30, 2019
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission on January 30, 2019.
Respectfully submitted,
Novartis AG
/s/ SHANNON THYME KLINGER |
/s/ HARRY KIRSCH |
Shannon Thyme Klinger |
Harry Kirsch |
General Counsel |
Chief Financial Officer |
Novartis Group |
Novartis Group |